The use of Therascreen® is not widespread in Portugal, but multiple technologies and platforms are available for molecular testing, which can potentially be used to detect PIK3CA mutational status in HR+/HER2-breast carcinoma samples. The gene discussed is PIK3CA; the disease is breast carcinoma.